It is only with this type of cooperation that essential research will continue and succeed.doi:10.1016/S0040-6090(02)00073-1Mitchell, Robert EChang, Sam SCurrent Opinion in UrologyMitchell RE, Chang SS. Current controversies in the treatment of high-risk prostate cancer. Curr Opin Urol. 2008...
Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges ... A brainstorming and consensus meeting organized by the German Cancer Aid focused on modern treatment of prostate cancer and promising innovative...
In recent years the pace of research in prostate cancer has increased dramatically. Creative ideas in combination with new and emerging technologies have led to an explosion of discovery. These types of advances in prostate cancer research presage an era of new treatment strategies based on an unde...
Credit: Unsplash/CC0 Public Domain The standard treatment for advanced metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). And even if this is efficient in the short term, 1/3 of PCa will become resistant to ADT and develop castration-resistant prostate cancer. A new study...
What causes prostate cancer is a subject of intensive research. It is likely that prostate cancer occurs due to many reasons. Predominately a disease of elderly men, the diagnosis of prostate cancer is rare before age 40 but increases dramatically thereafter. ...
With CNNs’ promising results in computer vision field15,21, the medical imaging research community has shifted their interest toward deep learning-based methods for designing CAD tools for cancer detection. As a widely used approach, most of proposed algorithms require user-drawn regions of interest...
Hormonal therapy, considered standard treatment for prostate cancer for forty years, is being reevaluated in light of more recent analysis of the studies conducted by the VA Cooperative Urologic Research Group (VACURG). Modalities reviewed include diethylstilbestrol, estramustine phosphate, aminoglutethimi...
treatment. De novo NEPC accounts for <2% of all prostate cancer at the time of diagnosis [66,67], but the incidence of NEPC has significantly increased with the clinical application of AR inhibitors [68,69,70,71]. The current incidence of NEPC accounts for 18–20% of patients with CRPC...
Given the indolent nature of prostate cancer and the substantial risks of treatment-related harms, the effects of cancer and treatment on quality of life are important patient-centered outcomes. Comparative effectiveness research, using observational cohorts, claims data and simulation models, enables ...
Starling et al., “Human Prostate Tissue Antigens Defined by Murine Monoclonal Antibodies”, Cancer Research, vol. 46, pp. 367-374, 1986. ;, vol. 46, pp. 367-374, 1986. Theyer et al., “Role of the MDR-1-Encoded Multiple Drug Resistance Phenotype In Prostate Cancer Cell Lines”, ...